

Notice of Allowability	Application No.	Applicant(s)
	10/727,514	THEZE ET AL.
	Examiner Prema M. Mertz	Art Unit 1646

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to the amendment filed 3/13/06.
2. The allowed claim(s) is/are 26-49, renumbered 1-24, respectively.
3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All
 - b) Some*
 - c) None
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) hereto or 2) to Paper No./Mail Date _____.
 - (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. Notice of References Cited (PTO-892)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)
3. Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date _____
4. Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. Notice of Informal Patent Application (PTO-152)
6. Interview Summary (PTO-413),
Paper No./Mail Date _____.
7. Examiner's Amendment/Comment
8. Examiner's Statement of Reasons for Allowance
9. Other _____.

Prema Mertz
Prema M Mertz
Primary Examiner
Art Unit: 1646

1. An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 C.F.R. § 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the Issue Fee.

Authorization for this Examiner's Amendment was given in a telephone interview with Vince Shier on 3/27/2006.

2. The application has been amended as follows:

IN THE CLAIMS:

Please amend the claims as set forth below:

26. (Currently Amended) A purified peptide consisting of SEQ ID NO: 2 or a peptide consisting of SEQ ID NO: 2 containing one conservative mutation, wherein said peptide binds to the IL-2 β chain or the monoclonal antibodies produced by H2-8 hybridoma.

28. (Currently Amended) The peptide of Claim 26, wherein said peptide is the peptide consisting of SEQ ID NO: 2 containing one conservative mutation.

37. (Currently Amended) A purified peptide consisting of SEQ ID NO.: 4 or a peptide consisting of SEQ ID NO: 4 containing one conservative mutation, wherein said peptide binds to the IL-2 β chain or the monoclonal antibodies produced by H2-8 hybridoma.

39. (Currently Amended) The peptide of Claim 37, wherein said peptide is the peptide consisting of SEQ ID NO: 4 containing one conservative mutation.

48. (Currently Amended) The peptide of Claim 37, wherein said peptide is the peptide consisting of SEQ ID NO: 2 containing one conservative mutation and induces SHC phosphorylation or induces the SHC/MAPK pathway.

49. (Currently Amended) The peptide of Claim 26, wherein said peptide is the peptide consisting of SEQ ID NO: 4 containing one conservative mutation and induces SHC phosphorylation or induces the SHC/MAPK pathway.

3. Claims 26-49 are allowable and have been renumbered 1-24 respectively.

Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Prema Mertz whose telephone number is (571) 272-0876. The examiner can normally be reached on Monday-Friday from 7:00AM to 3:30PM (Eastern time).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres, can be reached on (571) 272-0867.

Official papers filed by fax should be directed to (571) 273-8300. Faxed draft or informal communications with the examiner should be directed to (571) 273-0876.

Information regarding the status of an application may be obtained from the Patent application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Prema Mertz
Prema Mertz Ph.D., J.D.
Primary Examiner
Art Unit 1646
April 4, 2006